Program
Anti-HER2 Antibody-drug Conjugate IBI354
Its studies are mostly in Fallopian Tube Neoplasms · Breast Neoplasms, led by Innovent Biologics.
Drug pageAnti-HER2 Antibody-drug Conjugate IBI354: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Feb 5, 20253 company-led studies, 3 open or runningNext primary completion: Dec 28, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 33 open or running | phase 3since Feb 5, 2025 | Nov 23, 2022 | Dec 28, 2027phase 3 · NCT06834672 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2022First study: phase 2 study in Locally Advanced Unresectable or Metastatic Solid TumorsFirst studyNCT05636215 · 368 planned · Australia, China
- Feb 5, 2025Phase 3 study in Fallopian Tube NeoplasmsNCT06834672 · 450 enrolled · China
- Jan 15, 2026Phase 3 study in HER2-positive Breast CancerNCT07377643 · 540 planned · China
Ahead
- Dec 28, 2027Primary completion: phase 3 study in Fallopian Tube NeoplasmsNCT06834672
- Apr 28, 2028Primary completion: phase 3 study in HER2-positive Breast CancerNCT07377643
TargetBeta
ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07377643HER2-positive Breast Cancer · China | 3 | Recruiting | Apr 28, 2028 | 540 |
| NCT06834672Fallopian Tube Neoplasms · China | 3 | Active, not recruiting | Dec 28, 2027 | 450 |
| NCT05636215Locally Advanced Unresectable or Metastatic Solid Tumors · Australia, China | 2 | Recruiting | Apr 30, 2025 | 368 |
How it is read
Names in the registry
- “IBI354”, 3 entries
Conditions, from the studies’ own filings
- Fallopian Tube Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.